DO AVAILABLE VETERINARY MEDICINAL PRODUCTS MEET THE NEEDS OF THE MIDDLE EAST MARKET?

Dr Olivier Espeisse

International Federation Animal Health (IFAH)

Chairman of the Antibiotic Working Group
IFAH (International Federation Animal Health)

- IFAH, the International Federation for Animal Health, is the organisation representing manufacturers of veterinary medicines, vaccines and other animal health products in both developed and developing countries across five continents.
Plan

- 2 points of views
  - Middle East producers survey
  - IFAH (International Federation Animal Health) survey
Producers survey respondent base

- Countries
  - Egypt
  - Saudi
  - Jordan
  - Lebanon
- Producers
  - Poultry
  - Dairy
  - Sheep
- Timing
  - November 09
- Respondents
  - Managers
  - Veterinarians
Species gaps

- Horse
- Pigeon
- Fish
- Camel
Therapeutic gaps

- **Poultry**
  - Ornithobacterium rhinotracheale
  - Fungal diseases
  - Leukosis
  - Viral diseases (antiviral agents)
  - CRD
  - Avian Influenza

- **Cattle**
  - Neospora
  - Brucella (vaccine)
  - FMD
No molecule gap

- Nitrofurans
- Chloramphenicol
- Dimetridazole

None was seen as critical
Needs of producers to remain competitive

- **Poultry**
  - **Good veterinary services (surveillance)**
  - Improvement of cost base and especially **feed efficiency**
  - Effective therapies, **quality products**
  - New vaccines

- **Sheep and Dairy**
  - Traceability
  - **Productivity**
  - Zero withdrawal
Quality issues

- Packaging size
  - Seen as adequate except sometimes sheep

- Others
  - Almost all respondents mentioned quality issues
    - Counterfeit products
    - Quality of packaging / seals
    - Cold chain
    - Potency / quality of active principle / efficacy

- Distribution
  - Good
What is needed according to producers?

• In terms of products
  – 1. More quality of veterinary medicines
  – 2. More innovation

• In terms of veterinary and regulatory authorities
  – 1. Continuous implementation of manufacturing standards and inspections
  – 2. Control and testing of imported materials
  – 3. Continuous quality insurance inspections
  – 4. Residue testing
Our member companies reported

- Generics with low quality excipients (e.g. propylene glycols in ivermectins) which do not feature the necessary pharmacological properties
- Antibiotics with antagonistic properties in the same formulation
- Active principle issues (e.g. antihelmintics)
- Vaccines with no adequation with existing field strains
- Vaccine with live strains without enough attenuation
- Packaging defects
- Counterfeit products
Excellent efficacy of **Ivomec 1% injectable** are due to:
- Quality of **Ivermectin**
- Choice and Quality of **Excipient**

To kill ectoparasites you need very high concentrations of Ivermectin in the skin, only **Ivomec 1% inj.** reach such high levels, due to the quality of its Ivermectin and the choice of its excipient.

**Excipients**
glycerol Formol
**Propylene Glycol**: pharmaceutical grade
Leaking cap

Traces of leakage due to defective caps
Incomplete labeling
Conclusion

- What is needed?
  - Strong national or regional Registration Authorities, which are able not only to encourage the registration of good quality drugs but also able to control the products already available in the market.
  - Well organised distribution system
  - Strong Control Authorities
  - Strong and good functioning Veterinary Services
  - Strong National Veterinary Association, which is able to penalise and suspend Veterinarians who are not respecting their Veterinary responsibilities and ethics.
DO AVAILABLE VETERINARY MEDICINAL PRODUCTS MEET THE NEEDS OF THE MIDDLE EAST MARKET?
Thank you